Surgical outcomes of patients treated with ustekinumab vs. vedolizumab in inflammatory bowel disease: a matched case analysis
Sign Up to like & getrecommendations! Published in 2018 at "International Journal of Colorectal Disease"
DOI: 10.1007/s00384-018-3212-6
Abstract: AimThe association between preoperative use of monoclonal antibodies in inflammatory bowel disease (IBD) patients and postoperative complications is controversial, especially for the latest approved biologics, ustekinumab and vedolizumab, where data is limited. We hypothesized that… read more here.
Keywords: ustekinumab vedolizumab; inflammatory bowel; analysis; disease ... See more keywords
POS1420 RISK OF SERIOUS INFECTIONS IN OFFSPRING EXPOSED IN UTERO TO USTEKINUMAB OR VEDOLIZUMAB
Sign Up to like & getrecommendations! Published in 2021 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2021-eular.691
Abstract: Ustekinumab, an IL-12/23 inhibitor, is indicated in adult patients with inflammatory bowel disease (IBD), psoriasis (PsO), and psoriatic arthritis (PsA) and vedolizumab, an α4β7 receptor antagonist is indicated in IBD only. Both are monoclonal antibodies… read more here.
Keywords: offspring exposed; vedolizumab; risk; ustekinumab vedolizumab ... See more keywords